Auron Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$7.12M
- Investors
-
11
Auron Therapeutics General Information
Description
Operator of a biotechnology company intended to research and develop products focusing on the immunology and oncology medical fields. The company's research aims to cure cancer by changing the paradigm of cancer therapeutics from cell killing to the transformation of malignant cells into normal functioning cells, enabling researchers to focus on the advancement of novel drugs in areas of unmet medical need and offer life-saving, transformative medicines for cancer patients.
Contact Information
Website
www.aurontx.comCorporate Office
- 55 Chapel Street
- Suite 100
- Newton, MA 02458
- United States
Corporate Office
- 55 Chapel Street
- Suite 100
- Newton, MA 02458
- United States
Auron Therapeutics Timeline
Auron Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 13-Aug-2026 | $7.12M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series B1) | 23-Dec-2025 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 20-Oct-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Jan-2022 | $15.4M | Completed | Generating Revenue | ||
| 1. Seed Round | 16-Dec-2020 | $15.4M | $15.4M | Completed | Generating Revenue |
Auron Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B-2 | ||||||||
| Series A | 163,320,612 | $0.000100 | 8% | $0.31 | $0.31 | 1x | $0.31 | 48.6% |
| Seed | 50,309,444 | $0.000100 | 8% | $0.31 | $0.31 | 1x | $0.31 | 14.97% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Auron Therapeutics Comparisons
Industry
Financing
Details
Auron Therapeutics Competitors (59)
One of Auron Therapeutics’s 59 competitors is Sangamo Therapeutics, a Formerly VC-backed company based in Richmond, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| IFM Therapeutics | Venture Capital-Backed | Boston, MA |
Auron Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Auron Therapeutics Patents
Auron Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026183521-A1 | Compounds targeting cell states and uses thereof | Pending | 27-Feb-2025 | ||
| WO-2026080654-A1 | Technologies targeting cell states | Pending | 08-Oct-2024 | ||
| WO-2025231457-A1 | Technologies for modulating citk and cell states | Pending | 03-May-2024 | ||
| AU-2024256729-A1 | Technologies targeting cell states | Pending | 20-Apr-2023 | ||
| EP-4698166-A1 | Technologies targeting cell states | Pending | 20-Apr-2023 | C07D401/14 |
Auron Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Auron Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Therapy Acceleration Program (TAP) | Not-For-Profit Venture Capital | Minority | ||
| Apollo Health Ventures | Venture Capital | Minority | ||
| DCVC | Venture Capital | Minority | ||
| ACS BrightEdge | Corporate Venture Capital | Minority | ||
| Arkin Capital | Asset Manager | Minority |
Auron Therapeutics FAQs
-
When was Auron Therapeutics founded?
Auron Therapeutics was founded in 2018.
-
Where is Auron Therapeutics headquartered?
Auron Therapeutics is headquartered in Newton, MA.
-
What is the size of Auron Therapeutics?
Auron Therapeutics has 20 total employees.
-
What industry is Auron Therapeutics in?
Auron Therapeutics’s primary industry is Drug Discovery.
-
Is Auron Therapeutics a private or public company?
Auron Therapeutics is a Private company.
-
What is Auron Therapeutics’s current revenue?
The current revenue for Auron Therapeutics is .
-
How much funding has Auron Therapeutics raised over time?
Auron Therapeutics has raised $97.8M.
-
Who are Auron Therapeutics’s investors?
Therapy Acceleration Program (TAP), Apollo Health Ventures, DCVC, ACS BrightEdge, and Arkin Capital are 5 of 11 investors who have invested in Auron Therapeutics.
-
Who are Auron Therapeutics’s competitors?
Sangamo Therapeutics, Centrose, Adimab, Arvinas, and IFM Therapeutics are some of the 59 competitors of Auron Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
